PCSK9 向的自酶结合化合物:设计,合成和抗动脉样硬化评估
Hongyu Wu1, Ziwen Zhang1, Yongxing Xue1
1Department of Medicinal Chemistry, School of Pharmacy, Fudan University, Shanghai 201301, China.
Journal of medicinal chemistry
|April 14, 2025
概括
一种新型化合物W6有效降解PCSK9,显示出治疗动脉样硬化的前景. 这种自细胞结合化合物 (ATTEC) 为心血管疾病提供了新的治疗途径.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 动脉样硬化是一种复杂的心血管疾病,由多种细胞类型和机制驱动.
- 蛋白转化酶亚提利辛/凯类型-9 (PCSK9) 是动脉样硬化的关键治疗标.
- 目前的治疗主要利用生物药物,需要探索新的治疗策略.
研究的目的:
- 为了优化自细胞结合化合物 (ATTEC) 增强PCSK9降解.
- 评估优化化合物 (W6) 在治疗动脉样硬化的疗效.
- 评估W6作为抗动脉样硬化药物的潜力.
主要方法:
- 优化以前报告的ATTEC (OY3) 以开发化合物W6.6.
- 在体外和体内评估W6的抗动脉样硬化作用.
- 评估W6对肝细胞,内皮细胞,巨细胞和血管光滑肌细胞的影响.
主要成果:
- 与OY3.3相比,化合物W6显示PCSK9降解活性增加了5倍,生物可用性增加了6倍.
- W6对抗动脉样硬化的效果与市场上市的PCSK9抑制剂siRNA相似.
- W6在各种细胞类型中显示出有益的作用,这对动脉样硬化病理至关重要.
结论:
- 针对PCSK9的新型ATTEC,W6,是一种强大的PCSK9降解诱导剂.
- W6为动脉样硬化治疗提供了一个有前途的治疗候选者.
- 这项研究验证了ATTECs在疾病治疗中降解细胞内和细胞外蛋白质的潜力.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
596
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
596
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
499
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
499
Structure-Activity Relationships and Drug Design
679
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
679


